Vicky Makker, MD, on Endometrial Cancer: Lenvatinib Plus Pembrolizumab

March 19, 2021 By The ASCO Post Staff

Vicky Makker, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III findings showing that lenvatinib plus pembrolizumab may improve overall and progression-free survival, as well as overall response rate, compared with treatment of physician’s choice for advanced endometrial cancer. These results were achieved regardless of mismatch repair status following platinum-based chemotherapy (ID #10191).

Related Content